Fewer ads cause WebMD to revise outlook

Share this article:
Shares of WebMD parent company WebMD Health Corp dipped 12% yesterday after the company revised its outlook due to a lack of healthcare advertisers spending money with the firm. 

Shares fell $3.57, or 12.3%, to $25.46 in afternoon trading, the Associated Press reported. 

WebMD now expects net income for the year between $29.5 million and $37.5 million down from prior estimates for profit of $36.5 million to $46 million.

The AP reported that Citigroup analyst Mark Mahaney lowered his outlook on WebMD for 2008. He reiterated a "hold" rating on the stock.

Goldman Sachs analyst Jennifer Watson said the degree of the company's outlook revision and its explanation that drugmakers are hesitant to commit to advertising spending six to 12 months in advance, were surprising. 

“The biggest question is whether the slower trends are WebMD-specific or industry-wide," Watson wrote in a note to clients. “Specifically, we wonder if advertisers are testing lower-cost options, including emerging ad networks that deliver impressions across smaller consumer health and beauty sites.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.